英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读
史玉玲 . 英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读[J]. 诊断学理论与实践, 2021 , 20(01) : 37 -42 . DOI: 10.16150/j.1671-2870.2021.01.005
| [1] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019, 52(10):667-710. |
| [2] | 丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7):598-601. |
| [3] | 王晓晖. 西南4省市银屑病流行病学调查研究[J]. 哈尔滨医药, 2017, 37(5):426-427. |
| [4] | Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics[J]. J Am Acad Dermatol, 2019, 80(4):1029-1072. |
| [5] | Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020, 183(4):628-637. |
| [6] | Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance[J]. BMJ, 2012, 345:e6712. |
| [7] | NICE pathways. 2020 Musculoskeletal conditions overview[R/OL].(2020-02-25) http://pathways.nice.org.uk/pathways/musculoskeletalconditions#content=view_node%3Anodes-psoriatic-arthritis&path=view%3A/pathways/musculoskeletal_conditions/arthritis.xml In, Vol. [Accessed 26th February 2020]. |
| [8] | Samarasekera EJ, Smith CH, National Institute of Health and Care Excellence, et al. Psoriasis: guidance on assessment and referral[J]. Clin Med (Lond), 2014, 14(2):178-182. |
| [9] | Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants[J]. Pharmacoepidemiol Drug Saf, 2019, 28(3):296-304. |
| [10] | Ferreira C, Azevedo A, Nogueira M, et al. Management of psoriasis in pregnancy - a review of the evidence to date[J]. Drugs Context, 2020, 9:2019-11-6. |
| [11] | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019, 52(12):863-871. |
| [12] | Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoria-sis[J]. J Am Acad Dermatol, 2014, 70(1):178-186. |
| [13] | Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologi-cal therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S10-S20. |
| [14] | Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens[I]: CD19, CD20 and CD52)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S71-S82. |
| [15] | Ekong N, Curtis H, Ong E, et al. Monitoring of older HIV-1-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative[J]. HIV Med, 2020, 21(7):409-417. |
| [16] | Murdaca G, Negrini S, Pellecchio M, et al. Update upon the infection risk in patients receiving TNF alpha inhibitors[J]. Expert Opin Drug Saf, 2019, 18(3):219-229. |
| [17] | Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries[J]. Eur Respir J, 2015, 46(6):1563-1576. |
| [18] | Doherty SD, van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents[J]. J Am Acad Dermatol, 2008, 59(2):209-217. |
| [19] | Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond[J]. Clin Chest Med, 2019, 40(4):721-739. |
| [20] | Canouï E, Launay O. History and principles of vaccination[J]. Rev Mal Respir, 2019, 36(1):74-81. |
| [21] | Dobson R, Giovannoni G. Multiple sclerosis - a review[J]. Eur J Neurol, 2019, 26(1):27-40. |
| [22] | Generali E, Carrara G, Kallikourdis M, et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept[J]. Rheumatol Int, 2019, 39(2):239-243. |
| [23] | Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1(1):CD011535. |
| [24] | Oranges CM, Schaefer DJ. Implications of rheumatic di-sease and biological response-modifying agents in plastic surgery[J]. Plast Reconstr Surg, 2016, 138(1):158e. |
/
| 〈 |
|
〉 |
